TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07218341: Long-Term Safety of Pirtobrutinib in Participants From Study LOXO-BTK-20020 With BTKi Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Sponsor: Eli Lilly and Company · Phase: PHASE4 · Area: ONCOLOGY · Target Enrollment: 150 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$443,520

Rescue Site Savings

+$295,680

Unlock Full NCT07218341 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07218341 Rescue Dossier →